VISTA and PD-L1 synergistically predict poor prognosis in patients with extranodal natural killer/T-cell lymphoma

VISTA and PD-L1 synergistically predict poor prognosis in patients with extranodal natural killer/T-cell lymphoma

Although PD-1/PD-L1 blockade therapy confers salutary effects across cancer types, their efficacy in Extranodal Natural killer/T-cell lymphoma (ENKTCL) patients is limited and unpredictable. Here, we comprehensively evaluated the expression profile of a panel of immune-regulatory makers to identify...

Full description

Bibliographic Details
Main Authors: Hai-Xia He, Yan Gao, Jian-Chang Fu, Qiang-Hua Zhou, Xiao-Xiao Wang, Bing Bai, Peng-Fei Li, Cheng Huang, Qi-Xiang Rong, Li-Qin Ping, Yan-Xia He, Jia-Ying Mao, Xu Chen, Hui-Qiang Huang
Format: Article
Language:English
Published: Taylor & Francis Group 2021-01-01
Series:OncoImmunology
Subjects:
natural killer/t-cell lymphoma
pd-l1
✚-vista
immune checkpoint
antitumor immunity
Online Access:http://dx.doi.org/10.1080/2162402X.2021.1907059

Internet

http://dx.doi.org/10.1080/2162402X.2021.1907059

Similar Items